Objective:

This study examined the antihyperlipidemic and pleiotropic effects of weekly use of rosuvastatin in patients with statin-related adverse effects.

Methods:

Patients experiencing statinrelated adverse effects were included in this randomized controlled prospective study undertaken between 2008 and 2009. Rosuvastatin patients (n=22) received 10 mg of rosuvastatin weekly for 12 weeks, while control group (n=22) received no treatment. The following laboratory parameters were assessed at baseline and at week 12, blood lipids, alanin aminotransferase, creatinin kinase, P-selectin; mean platelet volume; Eselectin; tumor necrosis factor-?, and plasma interleukin-6.

Results:

Rosuvastatin and control groups were similar with regard to mean age (50.4±17.7 vs. 53.7±14.5 y, respectively) and sex distribution. An increase in HDLC, and a decrease in LDL-C and triglyceride levels were observed in the rosuvastatin group, while atherogenic dyslipidemia developed in controls. A significant difference was found between the two groups with regard to change in blood lipids from baseline to study endpoint (p=0.023, 0.015, and 0.043, respectively). There were not found significant differences in pleiotropic efficacy parameters. Alanin aninotransferase and creatinin kinase levels were improved in both groups.

Conclusion:

Weekly use of rosuvastatin had beneficial effect impact on lipid profile and restored alanin aninotransferase and creatinin kinase levels to normal. However, no benefit with regard to pleiotropic effects was detected. Further studies with a larger sample size and long duration are needed to evaluate on pleiotropic effects.

Keywords: